Zhonglin Chai

2.3k total citations · 2 hit papers
52 papers, 1.6k citations indexed

About

Zhonglin Chai is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Nephrology. According to data from OpenAlex, Zhonglin Chai has authored 52 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 14 papers in Nephrology. Recurrent topics in Zhonglin Chai's work include Chronic Kidney Disease and Diabetes (11 papers), COVID-19 Clinical Research Studies (7 papers) and Diabetes Management and Research (6 papers). Zhonglin Chai is often cited by papers focused on Chronic Kidney Disease and Diabetes (11 papers), COVID-19 Clinical Research Studies (7 papers) and Diabetes Management and Research (6 papers). Zhonglin Chai collaborates with scholars based in Australia, China and United Kingdom. Zhonglin Chai's co-authors include Mark E. Cooper, Paul Zimmet, George Alberti, Stephanie A. Amiel, Stefano Del Prato, Stefan R. Bornstein, Jean Claude Mbanya, Robert H. Eckel, Bernhard O. Boehm and Éric Renard and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Zhonglin Chai

52 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

New-Onset Diabetes in Covid-19

2020 541 citations Paul Zimmet, Mark E. Cooper et al. profile →
Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030

2023 105 citations Jinli Liu, Min Liu et al. The Lancet Regional Health - Western Pacific profile →

Peers

Countries citing papers authored by Zhonglin Chai

Since Specialization

Citations

This map shows the geographic impact of Zhonglin Chai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhonglin Chai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhonglin Chai more than expected).

Fields of papers citing papers by Zhonglin Chai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhonglin Chai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhonglin Chai. The network helps show where Zhonglin Chai may publish in the future.

Co-authorship network of co-authors of Zhonglin Chai

This figure shows the co-authorship network connecting the top 25 collaborators of Zhonglin Chai. A scholar is included among the top collaborators of Zhonglin Chai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhonglin Chai. Zhonglin Chai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe? 2025 ·International Journal of Molecular Sciences ·Ke Liu, (unknown), Zhonglin Chai, Fang Liu	4
2	Exploring the Potential of Claude 3 Opus in Renal Pathological Diagnosis: Performance Evaluation 2024 ·JMIR Medical Informatics ·(unknown), Ke Liu, (unknown), Zhonglin Chai, Fang Liu	2
3	The prognostic impact of the Stress Hyperglycemia Ratio on End‐Stage Renal Disease among patients with Diabetic Kidney Disease 2024 ·Diabetes Obesity and Metabolism ·Yutong Zou, Qing Yang, (unknown), Ke Liu, (unknown), (unknown), Zhonglin Chai, Mark E. Cooper, Fang Liu	3
4	To target cellular senescence in diabetic kidney disease: the known and the unknown 2024 ·Clinical Science ·Yuehan Wei, Shan Mou, Qing Yang, Fang Liu, Mark E. Cooper, Zhonglin Chai	8
5	Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice 2023 ·International Journal of Molecular Sciences ·Yutang Wang, (unknown), (unknown), (unknown), Paul K. Witting, Zhonglin Chai, Abdul Waheed Khan, (unknown), Kate M. Denton, Jonathan Golledge	10
6	Projected rapid growth in diabetes disease burden and economic burden in China: a spatio-temporal study from 2020 to 2030 breakdown → 2023 ·The Lancet Regional Health - Western Pacific ·Jinli Liu, Min Liu, Zhonglin Chai, Chao Li, (unknown), Mingwang Shen, Guihua Zhuang, Lei Zhang	105
7	Global Diabetes Prevalence in COVID-19 Patients and Contribution to COVID-19– Related Severity and Mortality: A Systematic Review and Meta-analysis 2023 ·Diabetes Care ·Rui Li, Mingwang Shen, Qianqian Yang, Christopher K. Fairley, Zhonglin Chai, (unknown), Jason J. Ong, (unknown), (unknown), Wenyi Hu, Zhuoru Zou, (unknown), (unknown), Guihua Zhuang, Lei Zhang	38
8	Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial Infections 2022 ·Pathogens ·(unknown), Zhonglin Chai, Mark E. Cooper, Paul Zimmet, Hua Guo, (unknown), Feifei Yang, (unknown), (unknown), Xiao Wang, Qin Zhong, Zongren Li, Peifang Zhang, Zhenhua Wu, (unknown), Lei Zhang, Kunlun He	1
9	Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990–2019 data 2022 ·Diabetologia ·Jinli Liu, Ruhai Bai, Zhonglin Chai, Mark E. Cooper, Paul Zimmet, Lei Zhang	77
10	New-onset COVID-19–related diabetes: an early indicator of multi-organ injury and mortally of SARS-CoV-2 infection 2022 ·PubMed ·Jin‐Kui Yang, Miaomiao Zhao, Jianmin Jin, Shi Liu, Peng Bai, Wei He, Fei Wu, Xiaofang Liu, Zhonglin Chai, Demin Han	11
11	A Modified MTS Proliferation Assay for Suspended Cells to Avoid the Interference by Hydralazine and β-Mercaptoethanol 2021 ·Assay and Drug Development Technologies ·Yutang Wang, (unknown), Guang Yang, (unknown), (unknown), Zhonglin Chai, (unknown), Fadi J. Charchar, Jonathan Golledge	16
12	Ultrasound combined with microbubbles enhances the renoprotective effects of methylprednisolone in rats with adriamycin-induced nephropathy 2021 ·European Journal of Pharmaceutical Sciences ·Shuting Ren, (unknown), Pengfei Sun, Tieqiao Wu, Aozhi Dai, Lina Chen, (unknown), (unknown), Xin Zhang, Zhonglin Chai	5
13	High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome 2021 ·Frontiers in Endocrinology ·Wenjun Wang, Zhonglin Chai, Mark E. Cooper, Paul Zimmet, Hua Guo, (unknown), Feifei Yang, (unknown), (unknown), Kai Zhang, Qin Zhong, Zongren Li, Peifang Zhang, Zhenhua Wu, (unknown), Lei Zhang, Kunlun He	9
14	An Improved 3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-Sulfophenyl)-2H-Tetrazolium Proliferation Assay to Overcome the Interference of Hydralazine 2020 ·Assay and Drug Development Technologies ·Yutang Wang, (unknown), Guang Yang, (unknown), Zhonglin Chai, Fadi J. Charchar, Jonathan Golledge	9
15	Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-β in diabetic nephropathy 2010 ·Kidney International ·(unknown), Tieqiao Wu, Aozhi Dai, (unknown), Phyllis Chew, Judy B. de Haan, Yu Wang, Ban‐Hock Toh, Hong‐Jian Zhu, Zemin Cao, Mark E. Cooper, Zhonglin Chai	27
16	Cell division autoantigen 1 plays a profibrotic role by modulating downstream signalling of TGF-β in a murine diabetic model of atherosclerosis 2009 ·Diabetologia ·(unknown), Yingfeng Tu, Tingting Wu, Terri J. Allen, Anna C. Calkin, Anna M.D. Watson, (unknown), Karin Jandeleit‐Dahm, B H Toh, Zhipeng Cao, Mark E. Cooper, Zhonglin Chai	29
17	Family history of coronary heart disease is associated with a higher incidence of nonalcoholic fatty liver disease: Central obesity the likely link 2007 ·Obesity Research & Clinical Practice ·Lei Zhang, (unknown), Zhonglin Chai, John B. Dixon	5
18	Antiproliferative Autoantigen CDA1 Transcriptionally Up-regulates p21Waf1/Cip1 by Activating p53 and MEK/ERK1/2 MAPK Pathways 2007 ·Journal of Biological Chemistry ·(unknown), (unknown), Tieqiao Wu, Zemin Cao, Richard J. Wilkins, Ban Hock Toh, Mark E. Cooper, Zhonglin Chai	62
19	17β-Hydroxysteroid Dehydrogenase Type XI Localizes to Human Steroidogenic Cells 2003 ·Endocrinology ·Zhonglin Chai, Phillip S. Brereton, Takashi Suzuki, Hironobu Sasano, Varuni Obeyesekere, Geneviève Escher, Richard Saffery, Peter J. Fuller, (unknown), Zygmunt S. Krozowski	56
20	Novel variant of p230 trans-Golgi network protein identified by serum from Sjögren's syndrome patient 2000 ·European Journal of Cell Biology ·Yoshito Tsukada, (unknown), Zhonglin Chai, (unknown), (unknown), John W. Sentry, Ban‐Hock Toh	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact